Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011151360 - AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS

Publication Number WO/2011/151360
Publication Date 08.12.2011
International Application No. PCT/EP2011/059009
International Filing Date 01.06.2011
IPC
C07D 403/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14containing three or more hetero rings
C07D 473/16 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
473Heterocyclic compounds containing purine ring systems
02with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6
16two nitrogen atoms
A61K 31/52 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
CPC
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
16Anti-Parkinson drugs
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07D 239/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46Two or more oxygen, sulfur or nitrogen atoms
47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
C07D 239/48
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46Two or more oxygen, sulfur or nitrogen atoms
48Two nitrogen atoms
Applicants
  • F. HOFFMANN-LA ROCHE AG [CH]/[CH] (AllExceptUS)
  • BAKER-GLENN, Charles [GB]/[GB] (UsOnly)
  • BURDICK, Daniel Jon [US]/[US] (UsOnly)
  • CHAMBERS, Mark [GB]/[GB] (UsOnly)
  • CHAN, Bryan K. [CA]/[US] (UsOnly)
  • CHEN, Huifen [US]/[US] (UsOnly)
  • ESTRADA, Anthony [US]/[US] (UsOnly)
  • GUNZNER, Janet L. [US]/[US] (UsOnly)
  • SHORE, Daniel [CA]/[US] (UsOnly)
  • SWEENEY, Zachary Kevin [US]/[US] (UsOnly)
  • WANG, Shumei [CA]/[US] (UsOnly)
  • ZHAO, Guiling [US]/[US] (UsOnly)
Inventors
  • BAKER-GLENN, Charles
  • BURDICK, Daniel Jon
  • CHAMBERS, Mark
  • CHAN, Bryan K.
  • CHEN, Huifen
  • ESTRADA, Anthony
  • GUNZNER, Janet L.
  • SHORE, Daniel
  • SWEENEY, Zachary Kevin
  • WANG, Shumei
  • ZHAO, Guiling
Agents
  • MUELLER-AFRAZ, Simona
Priority Data
61/351,53004.06.2010US
61/482,45504.05.2011US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
(FR) DÉRIVÉS D'AMINOPYRIMIDINE AU TITRE DE MODULATEURS DE LRRK2
Abstract
(EN) Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
(FR) L'invention concerne des composés de formule I : ou leurs sels de qualité pharmaceutique, où m, n, X, R1, R2, R3, R5, R6 et R7 sont tels que définis dans la présente. La présente invention concerne également des procédés de fabrication desdits composés et d'utilisation desdits composés dans le traitement de maladies associées au récepteur LRRK2, comme la maladie de Parkinson.
Related patent documents
CO12188550This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
CRCR2012-000591This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
TH1201006278This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau